Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
CTSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.71 - $1.61
Previous CloseN/A
Volume86.19K
Average Volume (3M)257.10K
Market Cap
$66.53M
Enterprise Value$103.11M
Total Cash (Recent Filing)$10.20M
Total Debt (Recent Filing)$27.06M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 06, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding62,761,806
10 Day Avg. Volume584,814
30 Day Avg. Volume257,103
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$1.00Price Target Upside-12.28% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cash ManagementThe company conducted an equity rights offering for gross proceeds of approximately $7.3M, resulting in a total pro forma cash position of $17.1M.
Commercial StrategyManagement plans to revamp associated rep accounts and territories in Germany to boost sales and drive strong growth by the second half of 2025.
Product RevenuesProduct revenues increased by 25% year-over-year and 6% quarter-over-quarter, driven by a 28% increase in direct sales outside of Germany and a 22% increase in global distributor sales.
Bears Say
Regulatory ChallengesThe company received a denial letter from the FDA regarding the 510(k) de novo application for DrugSorb-ATR during coronary artery bypass grafting surgery.
Regulatory UncertaintyThe company has not disclosed the specific issues related to the FDA denial, making it difficult to evaluate the chances of a successful appeal.
Revenue DeclineProduct revenues fell by approximately 3% year-over-year and 5% quarter-over-quarter due to falling direct sales in Germany.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.71 and its highest was $1.61 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $66.53M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Aug 07, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.08.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Overvalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,761,806 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went up 12.36%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
Cytosorbents Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-12.28% Downside)
$1.00 (-12.28% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.67%
12-Months-Change
Fundamentals
Return on Equity
-68.84%
Trailing 12-Months
Asset Growth
-10.18%
Trailing 12-Months
Company Description
Cytosorbents Corp
Cytosorbents Corporation (CTSO) is a medical technology company focused on developing and commercializing innovative products for critical care and cardiac surgery. The company specializes in blood purification technology, particularly through its flagship product, CytoSorb, which is designed to remove harmful substances from the bloodstream during severe inflammatory conditions. Cytosorbents operates primarily in the healthcare sector, targeting hospitals and medical facilities that require advanced treatment options for patients experiencing life-threatening conditions.
CTSO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive growth in product sales and strategic improvements in the German market, alongside significant regulatory challenges with the DrugSorb ATR product. While operational costs have increased, the company is optimistic about its appeal processes and potential future growth.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$1.00
▼(-12.28% Downside)
Technical Analysis
Ownership Overview
4.99% Insiders
5.90% Mutual Funds
0.14% Other Institutional Investors
85.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---